|Coordinate||161,788,164 bp (GRCm38)|
|Base Change||T ⇒ C (forward strand)|
|Gene Name||Fas ligand (TNF superfamily, member 6)|
|Synonym(s)||APT1LG1, CD178, CD95L, Fas-L, Tnfsf6|
|Chromosomal Location||161,780,689-161,788,495 bp (-)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene is a member of the tumor necrosis factor superfamily. The primary function of the encoded transmembrane protein is the induction of apoptosis triggered by binding to FAS. The FAS/FASLG signaling pathway is essential for immune system regulation, including activation-induced cell death (AICD) of T cells and cytotoxic T lymphocyte induced cell death. It has also been implicated in the progression of several cancers. Defects in this gene may be related to some cases of systemic lupus erythematosus (SLE). Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2014]
PHENOTYPE: Mice homozygous for a spontaneous allele, knock-out allele, or allele producting only the soluble isoform exhibit premature death due to the development of systemic lupus erythematosus, autoimmune glomerulonephritis, hepatomegaly, lymphadenopathy, and hypergammaglobulinaemia. [provided by MGI curators]
|Amino Acid Change||Aspartic acid changed to Glycine|
|Institutional Source||Beutler Lab|
|Gene Model||predicted gene model for protein(s): [ENSMUSP00000000834] [ENSMUSP00000141422]|
AA Change: D41G
|Predicted Effect||probably benign
PolyPhen 2 Score 0.000 (Sensitivity: 1.00; Specificity: 0.00)
|Predicted Effect||probably benign|
|Meta Mutation Damage Score||0.0898|
|Is this an essential gene?||Possibly essential (E-score: 0.512)|
|Candidate Explorer Status||CE: not good candidate; human score: -1.5; ML prob: 0.236|
Linkage Analysis Data
|Alleles Listed at MGI|
|Mode of Inheritance||Autosomal Recessive|
|Local Stock||Live Mice|
|Last Updated||2019-04-17 3:02 PM by Anne Murray|
|Record Created||2013-06-05 10:18 AM by Kuan-Wen Wang|
The riogrande phenotype was initially identified among G3 mice of the pedigree R0012, some of which exhibited decreased frequencys of T cells (Figure 1) and a diminished T-dependent antibody response to recombinant Semliki Forest virus (rSFV)-encoded β-galactosidase (rSFV-β-gal) (Figure 2).
|Nature of Mutation|
Whole exome HiSeq sequencing of the G1 grandsire identified 85 mutations. Both of the above anomalies were linked by continuous variable mapping to a mutation in Fasl: an A to G transition at base pair 161,788,164 (v38) on chromosome 1, or base pair 5,651 in the GenBank genomic region NC_000067. The strongest association was found with an additive model of inheritance to the normalized T cell frequency, wherein 8 variant homozygotes departed phenotypically from 43 unaffected mice that were either heterozygous (n = 26) or homozygous (n = 17) for the reference allele with a P value of 4.65 x 10-4 (Figure 3). The mutation corresponds to residue 332 in the mRNA sequence NM_010177 within exon 1 of 4 total exons.
The mutated nucleotide is indicated in red. The mutation results in an aspartic acid (D) to glycine (G) substitution at position 41 (D41G) in the FasL protein. The mutation is predicted by Polyphen-2 to be benign (score = 0.00).
Fasl encodes Fas ligand (FasL; alternatively, CD95L, TNFSF6, or CD178), a type II membrane protein and member of the tumor necrosis factor (TNF) family [reviewed in (1;2)]. For information about other members of the TNF family see the records for PanR1 (Tnf) and walla (Cd40lg). The 279 amino acid mouse FasL consists of an intracellular domain (ICD; amino acids 1-78), a transmembrane domain (amino acids 79-100), and an extracellular TNF homology domain (THD; amino acids 101-279) that contains the Fas receptor-binding site [Figure 4; (3); reviewed in (1)].
A proline-rich domain (PRD) and polyproline domain within the ICD (amino acids 4-69 and 45-51, respectively) facilitates the binding of Src homology 3 (SH3) or WW domain-containing proteins (e.g., Fyn, Nck, SNX9, SNX18, SNX33, and CD2BP1) to FasL [35606 Ghadimi,M.P. 2002; reviewed in (1;2)]. FasL association with SH3 domain-containing proteins facilitates FasL-mediated reverse signal transduction, FasL sorting to the lysosomal compartment in T and natural killer (NK) cells, trafficking to the membrane, and the recruitment of FasL and FasL-associated vesicles to the T cell/target cell interface (see “Background” and “Putative Mechanism” for more details on the function of FasL) (4-8). Members of the sorting nexin 9 protein family (e.g., SNX9, SNX18, SNX33) are endocytic and endosomal sorting proteins that regulate FasL trafficking (9;10). CD2BP1, a member of the pombe cdc15 homology (PCH) protein family, interacts with FasL and regulates actin reorganization to mediate immune synapse formation and T cell activation upon interaction with an antigen presenting cell (APC) (11-14). A comprehensive list of FasL interacting proteins is available in [reviewed in (1)]. In nontransformed murine CD8+ T cells, a construct containing only the FasL ICD was sufficient to recruit FasL to lipid rafts as well as to activate nuclear factor of activated T cells (NFAT) and activator protein 1 (AP1), mediate an increase in AKT levels and interferon-γ production as well as increase phosphorylation of ERK1/2, JNK, and FasL (15). Signaling via the FasL ICD dampened the lymphocyte activation-induced proliferative response by impairing the phosphorylation of PLCγ (see the record for queen), protein kinase C (PKC), and ERK1/2 (16).
FasL undergoes several posttranslational modifications. The FasL ICD has two conserved casein kinase I (CKI) binding motifs (amino acids 17-21) [reviewed in (1)]. TCR-induced CKI phosphorylation of FasL is correlated with FasL-associated reverse signaling in CD8+ T cells (15). Tyr7, 9, and 13 in human FasL and Tyr7 in mouse FasL are putative tyrosine phosphorylation sites [(17); reviewed in (1)]. Tyrosine phosphorylation as well as ubiquitination at lysines flanking the PRD, support the sorting of FasL to secretory lysosomes, resulting in FasL localization to the cell surface (18). The extracellular THD domain contains four putative Asn-linked glycosylation consensus sequences (Asn-X-Ser/Thr; Asn117, Asn182, Asn248, and Asn258) [(3;19); reviewed in (1;2)]. Asn-linked glycosylation is predicted to regulate FasL storage, stability, maturation, surface appearance, and secretion (20;21). Mutations of any of these residues did not significantly affect self-association or receptor binding, but did result in reduced FasL expression [reviewed in (1)]. A self-assembly (SA) region (amino acids 137-183) within the FasL extracellular domain mediates the formation of homotrimeric or hexameric complexes [(22); reviewed in (1)].
FasL occurs in both a membrane-bound (mFasL) and soluble form (sFasL) as a result of proteolytic processing of FasL. A disintegrin and metallopeptidase domain 10 (ADAM10; for information about ADAM family member, Adam17, please see the record wavedX) cleaves FasL between Lys127 and Gln128; ADAM10-induced cleavage of FasL in T cells regulated both FasL-induced cytotoxicity and activation-induced cell death (AICD; see the “Background” section for more information about AICD) (23). Following cleavage by ADAM10, FasL is further processed by signal peptide peptidase-like 2a (SPPL2a; amino acids 79-80), an intramembrane cleaving protease specific for type II transmembrane proteins [(23;24); reviewed in (1)]. Metalloproteinase-3 (MMP3) and MMP7 (see the record cartoon for information about MMP family member Mmp14) have also been linked to the cleavage of FasL between Lys127 and Gln128 in some cells (e.g., glandular epithelial cells) (25). The MMP7-induced cleavage is proposed to reduce the death-promoting activity of FasL and to subsequently promote tumor survival and the resistance to cytotoxic drugs [reviewed in (1)]. The function of the released N-terminal fragment is unknown, but it may enter the nucleus to regulate the transcription of target genes (24).
The riogrande mutation (D41G) is within the intracellular PRD domain.
Fasl is expressed in T cells (26), NK cells (27), and mature B cells (28) as well as in sites of immune privilege such as the eye, thyroid, lung, brain, placenta, and testis (29-34). Several tumor types including colorectal carcinoma, melanoma, head and neck carcinomas, hepatocellular carcinoma, lung carcinoma, and myeloma express FasL (35-39). In the rat, Fasl is moderately expressed in the small intestines, kidney and lung (3). Fasl expression in activated T cells and NK cells is transient (e.g., Fasl expression in NK cells is increased upon stimulation with CD16 ligation or cytokines such as IL-2 and IL-12), but Fasl expression in non-immune cells is typically constitutive [(17); reviewed in (40)].
In NK cells, FasL is stored in secretory lysosomes that mediate the secretion of cargo proteins upon stimulation (8). CD8+ cytotoxic T cells and some activated CD4+ T cells express mFasL on the cell surface (41). In activated CD4+ T helper 1 (TH1) cells, the surface expression of FasL is induced by several factors including antigens, anti-T cell receptor/CD3 antibodies, and mitogenic lectins (17); stimulation of CD4+ TH2 cells does not change FasL expression (3;42). In monocytes, FasL is localized intracellularly, but is subsequently released after exposure to either phytohemagglutinin (PHA), a lectin that induces T cell proliferation, or to immune complexes (7). FasL is released from cells by both proteolytic cleavage (in the form of sFasL) and in microvesicles in activated T cells (sFasL and mFasL) (43). In fibroblasts and epithelial cell lines, FasL is predominantly trafficked to the plasma membrane (44;45).
FasL expression is regulated at both the transcriptional and posttranslational levels. Factors including NFAT, NF-κB (see the record for finlay), c-Myc, IRF-1 (see the record for Endeka), stimulating protein 1 (SP-1), cyclin B1/Cdk1, and early growth response 3 (Egr-3) mediate the induction of Fasl upon T cell activation (17;46). The Fasl promoter has two NFAT sites; the more distal NFAT site is more essential for TCR-mediated Fasl expression in CD4+ T cells (47). Egr-3 is induced by NFAT and is predicted to act synergistically with NFAT to induce Fasl expression (48-50). SP-1 regulates basal Fasl expression in Jurkat T cells and the constitutive expression of Fasl in Sertoli cells (51) as well as the expression of Fasl in smooth muscle cells (52;53). After withdrawal of growth factors, forkhead family transcription factors induce the expression of Fasl (17). AP-1 mediates the stress- and TCR-induced expression of Fasl (17;54). The transcription of Fasl is negatively regulated by c-Fos (17). Class II transactivator (CIITA), a major histocompatiblility complex (MHC) class II transactivator, and retinoic acid block NFAT function and subsequently inhibit Fasl transcription (55;56). TGF-β downregulates c-Myc expression and subsequently inhibits TCR-induced Fasl expression (57).
The FasL/Fas receptor system has several functions: (i) acting as a pro-apoptotic factor, (ii) facilitating the removal of target cells by NK and cytotoxic T lymphocytes (CTLs), (iii) maintaining immune-privileged sites, (iv) preventing autoimmunity, (v) regulating resting T cell activation by acting as a non-apoptotic costimulatory ligand/receptor, (vi) acting as a proinflammatory signal, (vii) acting as a proliferative/promigratory signal, and (viii) assisting in tumor cell survival [reviewed in (1;58)]. Several of these functions are described in more detail, below.
FasL/Fas receptor-associated signaling induces apoptosis and mediates AICD of reactive T cells, a process that results in the termination of an immune response. AICD is essential in the prevention of lymphoid neoplasia (e.g., lymphoma and leukemia) and autoimmunity [(59); reviewed in (20)]. In Fas/FasL-induced apoptosis, binding of FasL to the Fas extracellular domain results in the formation of receptor microaggregates and a conformational change in the cytosolic domain of Fas (60;61). The conformational change in Fas results in the recruitment and binding of the adaptor protein Fas-associated protein with death domain (FADD) to the cytosolic death domain of Fas. Subsequently, FADD recruits the initiator caspase, caspase-8 (or -10), which interacts with the FADD N-terminal death effector domain; the Fas, FADD and caspase-8/-10 complex is referred to as the death-inducing signaling complex (DISC) [reviewed in (62)]. Formation of the DISC and subsequent auto-activation of caspase-8 through self-cleavage (63) requires the internalization of Fas to an endosomal compartment (64) or to lipid rafts to form signaling protein oligomeric transduction structures (SPOTS) (65). In the extrinsic apoptosis pathway in “type 1” cells, activated caspase-8 directly activates downstream effector caspases such as caspase-3, -6, and -7. The effector caspases subsequently cleave structural proteins and enzymes and the cell undergoes cell death [Figure 5; (29)]. In “type 2” cells (e.g., during negative selection of T cells and in B-cell maturation), low caspase-8 expression and/or caspase inhibitory molecules cause insufficient caspase activation [reviewed in (2)]. In these cells, FasL/Fas-mediated apoptosis occurs through the intrinsic apoptosis pathway (66). In the intrinsic pathway, caspase-8 mediates the cleavage of the pro-apoptotic Bcl-2 family member Bid to tBid and tBid translocates to the outer mitochondrial membrane (OMM) to activate Bcl-2 family members Bak and Bax (67;68). Bak oligomerizes, forming pores in the OMM that allow for the release of pro-apoptotic proteins such as cytochrome c and SMAC/DIABLO from the intermembrane space to the cytoplasm (69;70). Binding of cytochrome c and cytosolic ATP to apoptosis promoting factor-1 (Apaf-1) results in the formation of the apoptosome, a complex of cytochrome c, Apaf-1, and procaspase-9 [Figure 5; reviewed in (2)]. The apoptosome activates caspase-9, which subsequently cleaves caspase-3 and caspase-7 (71).
Constitutively expressed FasL protects immune privileged sites by triggering apoptosis of Fas-sensitive activated inflammatory cells entering into the sites (30). For example, constitutive expression of FasL in the eye is proposed to limit ocular inflammation (30). In Fasl-deficient mice (Faslgld; generalized lymphoproliferative disease (gld); MGI:1856384), exposure to herpes simplex virus or Toxoplasma gondii resulted in a more severe ocular inflammation than in wild-type mice (30;72).
For certain tumor cells, the constitutive expression of FasL, or its secretion from tumor-derived exosomes, can produce tumor-associated immune privilege, subsequently allowing malignant cells to evade immune surveillance (73). Tumor cells are rendered resistant to Fas-mediated apoptosis at several stages of Fas-associated signaling by secreting soluble decoy receptors (74), mediating apoptosis of tumor-infiltrating lymphocytes (TILs) (75;76), regulating Fas surface expression (77), altering the apoptosis signal at the DISC level, and/or by altering the expression of c-FLIP, FADD, XIAP, and/or caspase-8 [(78;79); reviewed in (2)].
mFasL and sFasL are functionally unique: mFasL triggers cell death induction, while sFasL mediates anti-apoptotic effects (80); sFasL often dowregulates part of the apoptotic activity of mFasL (81). In a mouse model of glaucoma, administration of mFasL led to retinal neurotoxicity, while administration of sFasL protected against apoptosis of retinal ganglion cells (82). In transfected lymphoma cells, sFasL blocked the apoptotic activity as well as opposed the pro-inflammatory activity of mFasL (83). Receptor-intereacting protein 1 (RIP1) is required for activation of downstream caspases after stimulation with mFasL. Cross-linking sFasL resulted in the formation of a larger, less efficient DISC complex than mFasL and bypassed the requirement for RIP1 (29). The association of sFasL with matrix proteins during physiological conditions would prevent cell death due to a reduced recruitment of RIP1 to the DISC, subsequently promoting the activation of non-apoptotic signaling pathways (84).
Reverse signaling/costimulatory molecule for T cell activation
TCR/CD3 complex engagement and a co-stimulatory receptor (e.g., CD28) signal are required for T cell activation (29). Without co-stimulation, the TCR/CD3-stimulated naïve CD4+ T cells undergo apoptosis (29). FasL can function as an accessory/costimulatory molecule during T cell activation, replacing the conventional CD28 co-stimulatory signal required for naïve T cell proliferation, and participates in reverse signaling (alternatively, retrograde signal transduction) in FasL-expressing cells [(29); reviewed in (1)]. In reverse signaling, the Fas receptor acts as the ligand for FasL, transmitting a signal into the FasL-expressing cell. Activation of FasL results in the recruitment of SH3-containing proteins including Fyn, Grb2, and the p85 subunit of PI3K to the cytoplasmic domain of FasL (5;15). CD8+ T cells require FasL co-stimulation to progress through the cell cycle, to proliferate, and to acquire cytolytic effector function, while FasL engagement in CD4+ T cells results in inhibition of the TCR-associated cell cycle progression and increased rates of apoptosis (85;86). During positive selection in the thymus, FasL-induced reverse signaling occurs upon the interaction of FasL-expressing thymocytes with Fas-positive stroma cells or thymic antigen-presenting cells (APCs) (29;87). In isolated human peripheral T cells, TCR/CD3/CD28-induced proliferation and activation were blocked by anti-FasL antibodies (88). In contrast to reports showing a costimulatory function for FasL (86;89), Luckerath et al. demonstrated that FasL plays an inhibitory role in reverse signaling in T cell proliferation (85;88). Luckerath et al. showed that the FasL ICD interacted with PSTPIP to recruit PTP-PEST, a negative regulator of ERK1/2/MAPK [Figure 6; (16)]. In addition, after posttranslational processing by ADAM10 and SPPL2a, the FasL ICD bound Lef-1 to negatively regulate Lef-1-dependent pro-proliferative Wnt signaling, subsequently impeding proliferation (16). Luckerath et al. propose that the conflicting costimulation results were due to the use of different FasL ICD constructs and expression systems between the studies and/or cross-linking induced by anti-FasL that led to a possibly non-physiologically strong (or weak) signal (16;85;86;89).
FasL-associated reverse signaling has also been documented in nonhematopoietic cells. In cancer cells, FasL-associated signaling enhanced cell migration and metastasis through activation of the hepatocyte growth factor (HGF) receptor Met (90). In the nervous system, FasL-associated signaling in Schwann cells resulted in activation of the Src and MAPK ERK1/2 pathways as well as the induction of nerve growth factor (NGF) secretion and subsequent NGF-stimulated neurite outgrowth (91).
Suppression of calcium influx upon T cell activation
TCR-mediated activation of T cells results in the triggering of calcium release from the endoplasmic reticulum (ER) (29). Emptying of the calcium stores of the ER subsequently results in the influx of extracellular calcium through calcium-release-activated calcium (CRAC) channels in the plasma membrane and a sustained calcium influx (92). Following T cell activation by an antigen, the elevated levels of intracellular free calcium results in activation of the transcription factor NFAT and the production of IL-2. Cross-linking of Fas on T cells before stimulation with anti-CD3 inhibited TCR-associated calcium influx indicating that Fas/FasL-mediated inhibition of calcium influx through the CRAC channels prevented T cell activation through an impairment of NFAT activation and IL-2 synthesis (93).
Mediation of CTL activity
Following target cell recognition, storage granules are transported to the site of cell-to-cell contact, where they fuse with the plasma membrane and release cytotoxic effector molecules including granzymes and perforin (see the record for Prime) into the immunological synapse (94). FasL expressed on activated CTLs or NK cells functions as a part of the perforin-independent effector machinery of cytotoxic immune cells and supplements the granzyme/perforin-mediated Fas+ target cell lysis pathway (17;95).
FasL/Fas-mediated signaling can also induce the p38, JNK1/2, ERK1/2 mitogen-activated protein kinase (MAPK), and NF-κB pathways to regulate cell proliferation, migration, and inflammation (29). FasL/Fas-mediated induction of NF-κB signaling in non-lymphoid cells such as hepatocytes, synoviocytes, macrophages, fibroblasts, and colonic and lung epithelial cells leads to the expression and release of inflammatory cytokines and chemokines such as IL-6, IL-1β, IL-8, TNF-α, MCP-1 (monocyte chemoattractant protein-1), IP-10 (interferon-gamma-induced protein 10) and PGE2 (prostaglandin E2) (96-99). The release of inflammatory factors may subsequently recruit inflammatory cells. FasL/Fas-associated inflammation is linked to several diseases including cystic fibrosis (100), arthritis (101;102), cancer (103), and acute respiratory distress syndrome (104).
In a model of heart disease, mFasL triggered pro-inflammatory cytokine production by monocytes and macrophages (105), while cardiac-specific expression of sFasL inhibited macrophage activation and pro-inflammatory cytokine production (106). To study the different functions of mFasL and sFasL in inflammation, mouse models were generated that solely expressed either mFasL (FaslΔs/Δs; Fasltm2.1Ast; MGI:4366051) or sFasL (FaslΔm/Δm; Fasltm1.1Ast; MGI:4366050) (80). The FaslΔm/Δm mice exhibited lymphadenopathy, splenomegaly, hyper-gammaglobulinaemia, and auto-nuclear antibodies, similar to gld mice (80). The titers of anti-DNA auto-antibodies were higher in the FaslΔm/Δm mice compared to gld mice and homozygotes had increased rates of developing hepatic tumors (80). The FaslΔs/Δs mice were phenotypically normal and had a normal life span (80). Taken together, sFasL appeared to be responsible for the pro-inflammatory function of FasL (80).
Autoimmunity and allograft rejection
The role of FasL in autoimmunity has been conflicting. Ectopic expression of FasL prevented autoimmune-mediated destruction of the thyroid (107). In contrast, an accelerated development of autoimmune diabetes was observed in nonobese diabetic mice upon FasL overexpression (108).
During kidney, heart, blood vessel, liver, lung, skin, thyroid, pancreatic islet cells, and bone marrow allograft rejection, recipient activated CD4+ and CD8+ T cells recognize the MHC molecules expressed on the allograft [reviewed in (109)]. FasL protects allogeneic grafts from immune rejection either through FasL-transduced allogeneic donor dendritic cells or by expressing FasL on the allogeneic tissue [reviewed in (109)]. The display of a chimeric streptavidin-FasL protein on cardiac vasculature prolonged graft survival through the selective deletion of alloreactive immune cells (110). In contrast, other studies found enhanced neutrophil recruitment and accelerated graft rejection upon ectopic overexpression of Fasl in tissue and tumor allograft studies (111-113). In the mouse, corneal transplants from gld mice were more prone to graft failure than those from wild-type mice (114). In addition, acute graft-versus-host disease in mice can be prevented with treatment with antibodies to both FasL and TNF-α (115;116).
Recovery after injury
Fas/FasL-associated signaling regulates neuronal development, growth, and differentiation (117). After sciatic nerve injury, FasL/Fas signaling triggered neurite outgrowth and branching as well as accelerated nerve regeneration (118). Following traumatic brain injury, the activation of Fas initially induced apoptosis, but later promoted regeneration by mediating neuronal branching (119). Fas/FasL-induced neurite growth required the recruitment of ezrin, a protein that links transmembrane proteins to the cytoskeleton, to Fas. Ezrin recruitment subsequently activated the small GTPase Rac1, resulting in process growth (119). FasL-associated activation of ERK further promoted process elongation and branching (118;119). Upregulation of FasL has been noted in axotomy-induced motor neuron death (120) and brain damage caused by ischemia (121;122).
Fas activation promoted liver regeneration after partial hepatectomy in mice (123). In contrast, massive hepatocyte apoptosis occurred in mice after intraperitoneal injection of Fas-activating antibodies (124). Fas/FasL activation also induced proliferation of quiescent hepatic stellate cells through FasL-induced phosphorylation of the EGFR and subsequent ERK activation (29).
In the heart, FasL/Fas signaling is proposed to mediate tissue damage after acute myocardial infarction (125;126). FasL overexpression in endothelial cells attenuated ischemia-reperfusion injury in the heart and led to a reduction in myocardial infarct size and neutrophil infiltration (127). In addition, FasL regulated Trypanosoma cruzi-induced acute myocarditis. Chronic infection of the heart resulted in a persistent inflammatory reaction of the myocardium, loss of cardiomyocytes, and development of fibrosis. In gld mice, cardiac infiltration and cardiomyocyte destruction were reduced in T. cruzi-induced acute myocarditis compared to BALB/c controls (128).
Several mutant mouse models of Fasl have been generated including the spontaneous gld model (83;129;130), an induced Fasl deletion (Fasl-/-; Fasltm1.1Lest; MGI:3032864) (131), a second spontaneous Fasl mouse model that lacks the transmembrane and THD domains (Fasldel; Fasldel1Hong; MGI:3803664) (132), and a knockin model that expresses a FasL protein that lacks the ICD but expresses a functional, truncated mFasL (Fasl ΔIntra; FaslTm1.1Cgm; MGI:4888490) (16). Loss of Fasl expression results in leukocytosis, splenomegaly, enlarged peripheral lymph nodes, and premature death by 4-5 months (131-133); examination of the gld mice determined that they had an inflammatory disease of the lung similar to interstitial pneumonitis (133). Approximately 40% of gld mice were anemic or exhibited significant leukocytosis (133). The livers of the Fasl-/- mice were larger than wild-type mice and had frequent moderate-to-severe lymphocytic infiltration (131). The glomerular size and cellularity of the kidneys of the Fasl-/- mice were increased compared to wild-type mice. At 9-10 weeks of age, tumors were evident at the cervical lymph nodes of the Fasldel mice (132). Fasl-/- mice exhibited larger lymph nodes than age matched homozygous gld mice at 3- to 5-months of age (131). Gld mice exhibited an increased occurrence of plasmacytoid tumors (134). The majority of thymocytes in younger (6-week) Fasldel thymocytes were mostly CD4+CD8+ cells in wild-type and Fasldel mice, while in older Fasldel mice the cell population was mainly abnormal CD3+B220+CD4−CD8− T cells that were proposed to be derived from conventional T cells that were repeatedly activated via the TCR complex (131;132). The gld and Fasl-/- mice produced autoantibodies, anti-DNA, and rheumatoid factor as well as developed a lupus-like autoimmune disease with symptoms that include glomerulonephritis, vasculitis, arthritis, and hypergammaglobulinemia (129;131-133;135;136).
Mutations in FASL are linked to autoimmune lymphoproliferative syndrome, type IB (ALPS; OMIM: #601859) (137). In ALPS, patients exhibit nonmalignant lymphadenopathy with splenomegaly (66). ALPS is an autosomal dominant disorder of FasL-induced apoptosis, resulting in the accumulation of autoreactive lymphocytes and the production of autoantibodies (138). Patients with ALPS may also exhibit includes Coombs-positive hemolytic anemia, chronic immune thrombocytopenic purpura, and neutropenia (66). ALPS patients have increased incidences of Hodgkin and non-Hodgkin lymphoma (139;140). A heterozygous mutation in FASL has been identified in a patient with systemic lupus erythematosus (SLE) [(141-143); reviewed in (144)]. The mutant FasL, an 84-bp deletion within exon 4 that resulted in a 28 amino acid in-frame deletion, exhibited decreased activity, decreased activation-induced cell death, and increased T cell proliferation upon activation (141). Mutations in FASL have also been linked to cervical carcinogenesis (145) as well as increased susceptibility to lung cancer (OMIM: #211980), breast cancer (146), and esophageal cancer (147-150). Changes in the levels of sFasL in the serum are considered to be prognostic or diagnostic marker for immune disorders (e.g., HIV infection and rheumatoid arthritis) and cancer (151). Patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) exhibit increased sFasL concentrations compared to healthy controls (152). The interaction of FasL with Fas is essential in keratinocyte apoptosis in SJS and TEN patients (153). In patients with SJS and TEN, the interaction of sFasL with keratinocyte Fas leads to widespread epidermal apoptosis with blister formation and skin detachment (152;154). A role for the FasL-Fas system has been proposed in autoimmune thyroiditis, multiple sclerosis, experimental allergic encephalomyelitis, and the pathogenesis of type-1 and type-2 diabetes [reviewed in (2)].
In both B and T cell development, apoptosis is essential to maintain immune cell homeostasis. Immature cells that fail to undergo proper V(D)J rearrangement and subsequently fail to express surface antigen receptors (BCR or TCR) undergo apoptosis. Fas/FasL-induced apoptosis is essential for the deletion of autoreactive thymocytes and immature B cells in the bone marrow [(155;156); reviewed in (41)]. BCR crosslinking or CD40 stimulation protect B lymphocytes from Fas-induced apoptosis through activation of Rel-NF-κB transcription factors (157) and the expression of c-FLIP, a regulator of caspase 8 activation (158). Activated B lymphocytes that bear low-affinity BCRs undergo apoptosis when Fas on their surface is ligated to FasL on intra-follicular CD4+ T cells and when they fail to receive a pro-survival signal through the BCR and CD40 (159). In combination with BCR-crosslinking and CD40 activation, Fas ligation is proposed to contribute to the activation, proliferation, and differentiation of B cells [reviewed in (41)].
Homozygous Fasl ΔIntra mice exhibited elevated plasma cells and increased generation of germinal center B cells, leading to increased titers of NP-specific IgM antibodies in the serum after immunization with 3-hydroxy 4-nitrophenylacetyl chicken gamma globulin (NP-CGG) (16). T-independent immunization of homozygous Fasl ΔIntra mice with NP-Ficoll resulted in increased plasma cell number as well as NP-specific IgM titers (16). In addition, the Fasl-/- and Fasldel mice exhibited increased IgG and IgM levels compared to wild-type levels (131;132). The riogrande mice exhibit reduced T-dependent IgG responses to rSFV. These findings indicate that the activation of B and/or T cells in the riogrande mice may be negatively affected by the Fasl mutation.
The riogrande mice also exhibited a semi-dominant decrease in the frequencies of peripheral T cells. The gld mice exhibit an increase in the numbers of peripheral blood lymphocytes (133;135). In addition, activation-induced proliferation of B cells, CD8+ cytotoxic T lymphocytes, and CD4+ T cells were increased in homozygous Fasl ΔIntra mice (16). The levels of several proliferation-associated genes including Irf4, a regulator of plasma cell differentiation, as well as Lef-1 target genes Nfat, Nfkb, Cycd1, and Fgf4, were upregulated in Fasl ΔIntra B cells (16). Luckerath et al. proposed that the differences in the immune responses of the Fasl ΔIntra mice compared to those in wild-type mice was due to a loss of inhibitory FasL reverse signaling in the Fasl ΔIntra.
The riogrande mutation within the PRD of FasL may be altering the association of FasLriogrande with a SH3 or WW-containing protein needed for B and/or T cell activation. SH3-containing proteins that interact with the PRD of FasL include Src-related kinases (e.g., Fyn, Lyn, Lck, Hck, Fgr, Src and Abl) and TCR-associated signaling adapter proteins (e.g., Grb2, Gads, the p85 subunit of PI3 kinase, and Nck) (4;160).
Riogrande genotyping is performed by amplifying the region containing the mutation using PCR, followed by sequencing of the amplified region to detect the single nucleotide transition.
Riogrande(F): 5’- ACATGGGCCATAGCAAGTCCCTAC-3’
Riogrande(R): 5’- TGACACCTGAGTCTCCTCCACAAG-3’
Riogrande_seq(F): 5’- TGCTAATCCATGTGCTAGGC-3’
Riogrande_seq(R): 5’- CCTCCACAAGGCTGTGAGAAG-3’
1) 94°C 2:00
2) 94°C 0:30
3) 55°C 0:30
4) 72°C 1:00
5) repeat steps (2-4) 40X
6) 72°C 10:00
7) 4°C ∞
The following sequence of 493 nucleotides is amplified (Chr.1: 161787854-161788346, GRCm38):
1 acatgggcca tagcaagtcc ctactcccac gcagcagagt caggttgcag ccaggaacgc
61 gagggctgct aatccatgtg ctaggcttac ctcacggagt tctgccagtt ccttctgcag
121 gtggaagagc tgatacattc ctaatcccat tccaaccaga gccaccagaa ccatgaaaaa
181 taccaccggt agccacagat ttgtgttgtg gtccttcttc tttagagggg tcagtggcgg
241 cagtgggagt ggttgtgatg gcggtggtag tggtgacaca ggtggtggtg gaggtggcgg
301 tctcctttgg tccggccctc taggcccaca agatggacag ggaaaaactg accctggagg
361 agcccaagat gaagtggcac tgctgtctac ccagaagatc tggggacatg ggtaattcat
421 gggctgctgc atggcaccca gccccaggaa agggtttcct tctcacagcc ttgtggagga
481 gactcaggtg tca
Primer binding sites are underlined and the sequencing primer is highlighted; the mutated nucleotide is shown in red text (T>C, Chr. (+) strand; A>G, sense strand).
1. Lettau, M., Paulsen, M., Schmidt, H., and Janssen, O. (2011) Insights into the Molecular Regulation of FasL (CD178) Biology. Eur J Cell Biol. 90, 456-466.
2. Ehrenschwender, M., and Wajant, H. (2009) The Role of FasL and Fas in Health and Disease. Adv Exp Med Biol. 647, 64-93.
3. Suda, T., Takahashi, T., Golstein, P., and Nagata, S. (1993) Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family. Cell. 75, 1169-1178.
4. Hane, M., Lowin, B., Peitsch, M., Becker, K., and Tschopp, J. (1995) Interaction of Peptides Derived from the Fas Ligand with the Fyn-SH3 Domain. FEBS Lett. 373, 265-268.
5. Ghadimi, M. P., Sanzenbacher, R., Thiede, B., Wenzel, J., Jing, Q., Plomann, M., Borkhardt, A., Kabelitz, D., and Janssen, O. (2002) Identification of Interaction Partners of the Cytosolic Polyproline Region of CD95 Ligand (CD178). FEBS Lett. 519, 50-58.
6. Lettau, M., Qian, J., Linkermann, A., Latreille, M., Larose, L., Kabelitz, D., and Janssen, O. (2006) The Adaptor Protein Nck Interacts with Fas Ligand: Guiding the Death Factor to the Cytotoxic Immunological Synapse. Proc Natl Acad Sci U S A. 103, 5911-5916.
7. Janssen, O., Qian, J., Linkermann, A., and Kabelitz, D. (2003) CD95 Ligand--Death Factor and Costimulatory Molecule? Cell Death Differ. 10, 1215-1225.
8. Blott, E. J., Bossi, G., Clark, R., Zvelebil, M., and Griffiths, G. M. (2001) Fas Ligand is Targeted to Secretory Lysosomes Via a Proline-Rich Domain in its Cytoplasmic Tail. J Cell Sci. 114, 2405-2416.
9. Thornhill, P. B., Cohn, J. B., Drury, G., Stanford, W. L., Bernstein, A., and Desbarats, J. (2007) A Proteomic Screen Reveals Novel Fas Ligand Interacting Proteins within Nervous System Schwann Cells. FEBS Lett. 581, 4455-4462.
10. Voss, M., Lettau, M., and Janssen, O. (2009) Identification of SH3 Domain Interaction Partners of Human FasL (CD178) by Phage Display Screening. BMC Immunol. 10, 53-2172-10-53.
11. Qian, J., Chen, W., Lettau, M., Podda, G., Zornig, M., Kabelitz, D., and Janssen, O. (2006) Regulation of FasL Expression: A SH3 Domain Containing Protein Family Involved in the Lysosomal Association of FasL. Cell Signal. 18, 1327-1337.
12. Badour, K., Zhang, J., Shi, F., McGavin, M. K., Rampersad, V., Hardy, L. A., Field, D., and Siminovitch, K. A. (2003) The Wiskott-Aldrich Syndrome Protein Acts Downstream of CD2 and the CD2AP and PSTPIP1 Adaptors to Promote Formation of the Immunological Synapse. Immunity. 18, 141-154.
13. Yang, H., and Reinherz, E. L. (2006) CD2BP1 Modulates CD2-Dependent T Cell Activation Via Linkage to Protein Tyrosine Phosphatase (PTP)-PEST. J Immunol. 176, 5898-5907.
14. Baum, W., Kirkin, V., Fernandez, S. B., Pick, R., Lettau, M., Janssen, O., and Zornig, M. (2005) Binding of the Intracellular Fas Ligand (FasL) Domain to the Adaptor Protein PSTPIP Results in a Cytoplasmic Localization of FasL. J Biol Chem. 280, 40012-40024.
15. Sun, M., Ames, K. T., Suzuki, I., and Fink, P. J. (2006) The Cytoplasmic Domain of Fas Ligand Costimulates TCR Signals. J Immunol. 177, 1481-1491.
16. Luckerath, K., Kirkin, V., Melzer, I. M., Thalheimer, F. B., Siele, D., Milani, W., Adler, T., Aguilar-Pimentel, A., Horsch, M., Michel, G., Beckers, J., Busch, D. H., Ollert, M., Gailus-Durner, V., Fuchs, H., Hrabe de Angelis, M., Staal, F. J., Rajalingam, K., Hueber, A. O., Strobl, L. J., Zimber-Strobl, U., and Zornig, M. (2011) Immune Modulation by Fas Ligand Reverse Signaling: Lymphocyte Proliferation is Attenuated by the Intracellular Fas Ligand Domain. Blood. 117, 519-529.
17. Lettau, M., Paulsen, M., Kabelitz, D., and Janssen, O. (2009) FasL Expression and Reverse Signalling. Results Probl Cell Differ. 49, 49-61.
18. Zuccato, E., Blott, E. J., Holt, O., Sigismund, S., Shaw, M., Bossi, G., and Griffiths, G. M. (2007) Sorting of Fas Ligand to Secretory Lysosomes is Regulated by Mono-Ubiquitylation and Phosphorylation. J Cell Sci. 120, 191-199.
19. Bodmer, J. L., Schneider, P., and Tschopp, J. (2002) The Molecular Architecture of the TNF Superfamily. Trends Biochem Sci. 27, 19-26.
20. Lettau, M., Paulsen, M., Kabelitz, D., and Janssen, O. (2008) Storage, Expression and Function of Fas Ligand, the Key Death Factor of Immune Cells. Curr Med Chem. 15, 1684-1696.
21. Voss, M., Lettau, M., Paulsen, M., and Janssen, O. (2008) Posttranslational Regulation of Fas Ligand Function. Cell Commun Signal. 6, 11-811X-6-11.
22. Holler, N., Tardivel, A., Kovacsovics-Bankowski, M., Hertig, S., Gaide, O., Martinon, F., Tinel, A., Deperthes, D., Calderara, S., Schulthess, T., Engel, J., Schneider, P., and Tschopp, J. (2003) Two Adjacent Trimeric Fas Ligands are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex. Mol Cell Biol. 23, 1428-1440.
23. Schulte, M., Reiss, K., Lettau, M., Maretzky, T., Ludwig, A., Hartmann, D., de Strooper, B., Janssen, O., and Saftig, P. (2007) ADAM10 Regulates FasL Cell Surface Expression and Modulates FasL-Induced Cytotoxicity and Activation-Induced Cell Death. Cell Death Differ. 14, 1040-1049.
24. Kirkin, V., Cahuzac, N., Guardiola-Serrano, F., Huault, S., Luckerath, K., Friedmann, E., Novac, N., Wels, W. S., Martoglio, B., Hueber, A. O., and Zornig, M. (2007) The Fas Ligand Intracellular Domain is Released by ADAM10 and SPPL2a Cleavage in T-Cells. Cell Death Differ. 14, 1678-1687.
25. Tanaka, M., Itai, T., Adachi, M., and Nagata, S. (1998) Downregulation of Fas Ligand by Shedding. Nat Med. 4, 31-36.
26. Suda, T., Okazaki, T., Naito, Y., Yokota, T., Arai, N., Ozaki, S., Nakao, K., and Nagata, S. (1995) Expression of the Fas Ligand in Cells of T Cell Lineage. J Immunol. 154, 3806-3813.
27. Arase, H., Arase, N., and Saito, T. (1995) Fas-Mediated Cytotoxicity by Freshly Isolated Natural Killer Cells. J Exp Med. 181, 1235-1238.
28. Hahne, M., Renno, T., Schroeter, M., Irmler, M., French, L., Bornard, T., MacDonald, H. R., and Tschopp, J. (1996) Activated B Cells Express Functional Fas Ligand. Eur J Immunol. 26, 721-724.
29. Brint, E., O'Callaghan, G., and Houston, A. (2013) Life in the Fas Lane: Differential Outcomes of Fas Signaling. Cell Mol Life Sci. 70, 4085-4099.
30. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., and Ferguson, T. A. (1995) Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege. Science. 270, 1189-1192.
31. Gochuico, B. R., Miranda, K. M., Hessel, E. M., De Bie, J. J., Van Oosterhout, A. J., Cruikshank, W. W., and Fine, A. (1998) Airway Epithelial Fas Ligand Expression: Potential Role in Modulating Bronchial Inflammation. Am J Physiol. 274, L444-9.
32. Sabelko-Downes, K. A., Cross, A. H., and Russell, J. H. (1999) Dual Role for Fas Ligand in the Initiation of and Recovery from Experimental Allergic Encephalomyelitis. J Exp Med. 189, 1195-1205.
33. Hunt, J. S., Vassmer, D., Ferguson, T. A., and Miller, L. (1997) Fas Ligand is Positioned in Mouse Uterus and Placenta to Prevent Trafficking of Activated Leukocytes between the Mother and the Conceptus. J Immunol. 158, 4122-4128.
34. Bechmann, I., Mor, G., Nilsen, J., Eliza, M., Nitsch, R., and Naftolin, F. (1999) FasL (CD95L, Apo1L) is Expressed in the Normal Rat and Human Brain: Evidence for the Existence of an Immunological Brain Barrier. Glia. 27, 62-74.
35. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. (1996) The Fas Counterattack: Fas-Mediated T Cell Killing by Colon Cancer Cells Expressing Fas Ligand. J Exp Med. 184, 1075-1082.
36. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J., and Tschopp, J. (1996) Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape. Science. 274, 1363-1366.
37. Hoffmann, T. K., Dworacki, G., Tsukihiro, T., Meidenbauer, N., Gooding, W., Johnson, J. T., and Whiteside, T. L. (2002) Spontaneous Apoptosis of Circulating T Lymphocytes in Patients with Head and Neck Cancer and its Clinical Importance. Clin Cancer Res. 8, 2553-2562.
38. Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salerno, C. T., Knapp, D. J., Green, D. R., and Kratzke, R. A. (1997) Human Lung Carcinomas Express Fas Ligand. Cancer Res. 57, 1007-1012.
39. Villunger, A., Egle, A., Marschitz, I., Kos, M., Bock, G., Ludwig, H., Geley, S., Kofler, R., and Greil, R. (1997) Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-Induced Suppression of Immune Surveillance. Blood. 90, 12-20.
40. Ramaswamy, M., Cleland, S. Y., Cruz, A. C., and Siegel, R. M. (2009) Many Checkpoints on the Road to Cell Death: Regulation of Fas-FasL Interactions and Fas Signaling in Peripheral Immune Responses. Results Probl Cell Differ. 49, 17-47.
41. Strasser, A., Jost, P. J., and Nagata, S. (2009) The Many Roles of FAS Receptor Signaling in the Immune System. Immunity. 30, 180-192.
42. Janssen, O., Sanzenbacher, R., and Kabelitz, D. (2000) Regulation of Activation-Induced Cell Death of Mature T-Lymphocyte Populations. Cell Tissue Res. 301, 85-99.
43. Monleon, I., Martinez-Lorenzo, M. J., Monteagudo, L., Lasierra, P., Taules, M., Iturralde, M., Pineiro, A., Larrad, L., Alava, M. A., Naval, J., and Anel, A. (2001) Differential Secretion of Fas Ligand- Or APO2 ligand/TNF-Related Apoptosis-Inducing Ligand-Carrying Microvesicles during Activation-Induced Death of Human T Cells. J Immunol. 167, 6736-6744.
44. Lorz, C., Ortiz, A., Justo, P., Gonzalez-Cuadrado, S., Duque, N., Gomez-Guerrero, C., and Egido, J. (2000) Proapoptotic Fas Ligand is Expressed by Normal Kidney Tubular Epithelium and Injured Glomeruli. J Am Soc Nephrol. 11, 1266-1277.
45. Saitoh, A., Kawanabe, T., Weidong, H., Kayagaki, N., Kawamura, T., Yagita, H., Okumura, K., and Shimada, S. (2000) Selective Upregulation of Fibroblast Fas Ligand Expression, and Prolongation of Fas/Fas Ligand-Mediated Skin Allograft Survival, by Retinoic Acid: The Skin as a Retinoide-Inducible Immune Privilege Site. J Invest Dermatol. 115, 154-161.
46. Brunner, T., Kasibhatla, S., Pinkoski, M. J., Frutschi, C., Yoo, N. J., Echeverri, F., Mahboubi, A., and Green, D. R. (2000) Expression of Fas Ligand in Activated T Cells is Regulated by c-Myc. J Biol Chem. 275, 9767-9772.
47. Latinis, K. M., Norian, L. A., Eliason, S. L., and Koretzky, G. A. (1997) Two NFAT Transcription Factor Binding Sites Participate in the Regulation of CD95 (Fas) Ligand Expression in Activated Human T Cells. J Biol Chem. 272, 31427-31434.
48. Dzialo-Hatton, R., Milbrandt, J., Hockett, R. D.,Jr, and Weaver, C. T. (2001) Differential Expression of Fas Ligand in Th1 and Th2 Cells is Regulated by Early Growth Response Gene and NF-AT Family Members. J Immunol. 166, 4534-4542.
49. Mittelstadt, P. R., and Ashwell, J. D. (1999) Role of Egr-2 in Up-Regulation of Fas Ligand in Normal T Cells and Aberrant Double-Negative Lpr and Gld T Cells. J Biol Chem. 274, 3222-3227.
50. Rengarajan, J., Mittelstadt, P. R., Mages, H. W., Gerth, A. J., Kroczek, R. A., Ashwell, J. D., and Glimcher, L. H. (2000) Sequential Involvement of NFAT and Egr Transcription Factors in FasL Regulation. Immunity. 12, 293-300.
51. McClure, R. F., Heppelmann, C. J., and Paya, C. V. (1999) Constitutive Fas Ligand Gene Transcription in Sertoli Cells is Regulated by Sp1. J Biol Chem. 274, 7756-7762.
52. Kavurma, M. M., Bobryshev, Y., and Khachigian, L. M. (2002) Ets-1 Positively Regulates Fas Ligand Transcription Via Cooperative Interactions with Sp1. J Biol Chem. 277, 36244-36252.
53. Kavurma, M. M., Santiago, F. S., Bonfoco, E., and Khachigian, L. M. (2001) Sp1 Phosphorylation Regulates Apoptosis Via Extracellular FasL-Fas Engagement. J Biol Chem. 276, 4964-4971.
54. Matsui, K., Xiao, S., Fine, A., and Ju, S. T. (2000) Role of Activator Protein-1 in TCR-Mediated Regulation of the Murine Fasl Promoter. J Immunol. 164, 3002-3008.
55. Gourley, T. S., and Chang, C. H. (2001) Cutting Edge: The Class II Transactivator Prevents Activation-Induced Cell Death by Inhibiting Fas Ligand Gene Expression. J Immunol. 166, 2917-2921.
56. Lee, M. O., Kang, H. J., Kim, Y. M., Oum, J. H., and Park, J. (2002) Repression of FasL Expression by Retinoic Acid Involves a Novel Mechanism of Inhibition of Transactivation Function of the Nuclear Factors of Activated T-Cells. Eur J Biochem. 269, 1162-1170.
57. Genestier, L., Kasibhatla, S., Brunner, T., and Green, D. R. (1999) Transforming Growth Factor beta1 Inhibits Fas Ligand Expression and Subsequent Activation-Induced Cell Death in T Cells Via Downregulation of c-Myc. J Exp Med. 189, 231-239.
58. Walczak, H. (2013) Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation. Cold Spring Harb Perspect Biol. 5, a008698.
59. Curtin, J. F., and Cotter, T. G. (2003) Live and Let Die: Regulatory Mechanisms in Fas-Mediated Apoptosis. Cell Signal. 15, 983-992.
60. Algeciras-Schimnich, A., Shen, L., Barnhart, B. C., Murmann, A. E., Burkhardt, J. K., and Peter, M. E. (2002) Molecular Ordering of the Initial Signaling Events of CD95. Mol Cell Biol. 22, 207-220.
61. Scott, F. L., Stec, B., Pop, C., Dobaczewska, M. K., Lee, J. J., Monosov, E., Robinson, H., Salvesen, G. S., Schwarzenbacher, R., and Riedl, S. J. (2009) The Fas-FADD Death Domain Complex Structure Unravels Signalling by Receptor Clustering. Nature. 457, 1019-1022.
62. Li, J., Yin, Q., and Wu, H. (2013) Structural Basis of Signal Transduction in the TNF Receptor Superfamily. Adv Immunol. 119, 135-153.
63. Salvesen, G. S., and Dixit, V. M. (1999) Caspase Activation: The Induced-Proximity Model. Proc Natl Acad Sci U S A. 96, 10964-10967.
64. Lee, K. H., Feig, C., Tchikov, V., Schickel, R., Hallas, C., Schutze, S., Peter, M. E., and Chan, A. C. (2006) The Role of Receptor Internalization in CD95 Signaling. EMBO J. 25, 1009-1023.
65. Gajate, C., and Mollinedo, F. (2001) The Antitumor Ether Lipid ET-18-OCH(3) Induces Apoptosis through Translocation and Capping of Fas/CD95 into Membrane Rafts in Human Leukemic Cells. Blood. 98, 3860-3863.
66. Randhawa, S. R., Chahine, B. G., Lowery-Nordberg, M., Cotelingam, J. D., and Casillas, A. M. (2010) Underexpression and Overexpression of Fas and Fas Ligand: A Double-Edged Sword. Ann Allergy Asthma Immunol. 104, 286-292.
67. Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998) Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis. Cell. 94, 491-501.
68. Wei, M. C., Lindsten, T., Mootha, V. K., Weiler, S., Gross, A., Ashiya, M., Thompson, C. B., and Korsmeyer, S. J. (2000) TBID, a Membrane-Targeted Death Ligand, Oligomerizes BAK to Release Cytochrome c. Genes Dev. 14, 2060-2071.
69. Barnhart, B. C., Alappat, E. C., and Peter, M. E. (2003) The CD95 Type I/type II Model. Semin Immunol. 15, 185-193.
70. Peter, M. E., and Krammer, P. H. (2003) The CD95(APO-1/Fas) DISC and Beyond. Cell Death Differ. 10, 26-35.
71. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997) Cytochrome c and dATP-Dependent Formation of Apaf-1/caspase-9 Complex Initiates an Apoptotic Protease Cascade. Cell. 91, 479-489.
72. Hu, M. S., Schwartzman, J. D., Yeaman, G. R., Collins, J., Seguin, R., Khan, I. A., and Kasper, L. H. (1999) Fas-FasL Interaction Involved in Pathogenesis of Ocular Toxoplasmosis in Mice. Infect Immun. 67, 928-935.
73. O'Connell, J., Bennett, M. W., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. (1999) The Fas Counterattack: Cancer as a Site of Immune Privilege. Immunol Today. 20, 46-52.
74. Pitti, R. M., Marsters, S. A., Lawrence, D. A., Roy, M., Kischkel, F. C., Dowd, P., Huang, A., Donahue, C. J., Sherwood, S. W., Baldwin, D. T., Godowski, P. J., Wood, W. I., Gurney, A. L., Hillan, K. J., Cohen, R. L., Goddard, A. D., Botstein, D., and Ashkenazi, A. (1998) Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer. Nature. 396, 699-703.
75. Okada, K., Komuta, K., Hashimoto, S., Matsuzaki, S., Kanematsu, T., and Koji, T. (2000) Frequency of Apoptosis of Tumor-Infiltrating Lymphocytes Induced by Fas Counterattack in Human Colorectal Carcinoma and its Correlation with Prognosis. Clin Cancer Res. 6, 3560-3564.
76. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., and Shanahan, F. (1998) The Fas Counterattack in Vivo: Apoptotic Depletion of Tumor-Infiltrating Lymphocytes Associated with Fas Ligand Expression by Human Esophageal Carcinoma. J Immunol. 160, 5669-5675.
77. Peshes-Yaloz, N., Rosen, D., Sondel, P. M., Krammer, P. H., and Berke, G. (2007) Up-Regulation of Fas (CD95) Expression in Tumour Cells in Vivo. Immunology. 120, 502-511.
78. Huerta, S., Heinzerling, J. H., Anguiano-Hernandez, Y. M., Huerta-Yepez, S., Lin, J., Chen, D., Bonavida, B., and Livingston, E. H. (2007) Modification of Gene Products Involved in Resistance to Apoptosis in Metastatic Colon Cancer Cells: Roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res. 142, 184-194.
79. Wang, L., Azad, N., Kongkaneramit, L., Chen, F., Lu, Y., Jiang, B. H., and Rojanasakul, Y. (2008) The Fas Death Signaling Pathway Connecting Reactive Oxygen Species Generation and FLICE Inhibitory Protein Down-Regulation. J Immunol. 180, 3072-3080.
80. O'Reilly, L. A., Tai, L., Lee, L., Kruse, E. A., Grabow, S., Fairlie, W. D., Haynes, N. M., Tarlinton, D. M., Zhang, J. G., Belz, G. T., Smyth, M. J., Bouillet, P., Robb, L., and Strasser, A. (2009) Membrane-Bound Fas Ligand Only is Essential for Fas-Induced Apoptosis. Nature. 461, 659-663.
81. Suda, T., Hashimoto, H., Tanaka, M., Ochi, T., and Nagata, S. (1997) Membrane Fas Ligand Kills Human Peripheral Blood T Lymphocytes, and Soluble Fas Ligand Blocks the Killing. J Exp Med. 186, 2045-2050.
82. Gregory, M. S., Hackett, C. G., Abernathy, E. F., Lee, K. S., Saff, R. R., Hohlbaum, A. M., Moody, K. S., Hobson, M. W., Jones, A., Kolovou, P., Karray, S., Giani, A., John, S. W., Chen, D. F., Marshak-Rothstein, A., and Ksander, B. R. (2011) Opposing Roles for Membrane Bound and Soluble Fas Ligand in Glaucoma-Associated Retinal Ganglion Cell Death. PLoS One. 6, e17659.
83. Hohlbaum, A. M., Moe, S., and Marshak-Rothstein, A. (2000) Opposing Effects of Transmembrane and Soluble Fas Ligand Expression on Inflammation and Tumor Cell Survival. J Exp Med. 191, 1209-1220.
84. Morgan, M. J., Kim, Y. S., and Liu, Z. G. (2009) Membrane-Bound Fas Ligand Requires RIP1 for Efficient Activation of Caspase-8 within the Death-Inducing Signaling Complex. J Immunol. 183, 3278-3284.
85. Desbarats, J., Duke, R. C., and Newell, M. K. (1998) Newly Discovered Role for Fas Ligand in the Cell-Cycle Arrest of CD4+ T Cells. Nat Med. 4, 1377-1382.
86. Suzuki, I., and Fink, P. J. (1998) Maximal Proliferation of Cytotoxic T Lymphocytes Requires Reverse Signaling through Fas Ligand. J Exp Med. 187, 123-128.
87. Boursalian, T. E., and Fink, P. J. (2003) Mutation in Fas Ligand Impairs Maturation of Thymocytes Bearing Moderate Affinity T Cell Receptors. J Exp Med. 198, 349-360.
88. Paulsen, M., Mathew, B., Qian, J., Lettau, M., Kabelitz, D., and Janssen, O. (2009) FasL Cross-Linking Inhibits Activation of Human Peripheral T Cells. Int Immunol. 21, 587-598.
89. Sun, M., Lee, S., Karray, S., Levi-Strauss, M., Ames, K. T., and Fink, P. J. (2007) Cutting Edge: Two Distinct Motifs within the Fas Ligand Tail Regulate Fas Ligand-Mediated Costimulation. J Immunol. 179, 5639-5643.
90. Lin, H. C., Lai, P. Y., Lin, Y. P., Huang, J. Y., and Yang, B. C. (2012) Fas Ligand Enhances Malignant Behavior of Tumor Cells through Interaction with Met, Hepatocyte Growth Factor Receptor, in Lipid Rafts. J Biol Chem. 287, 20664-20673.
91. Mimouni-Rongy, M., White, J. H., Weinstein, D. E., Desbarats, J., and Almazan, G. (2011) Fas Ligand Acts as a Counter-Receptor in Schwann Cells and Induces the Secretion of Bioactive Nerve Growth Factor. J Neuroimmunol. 230, 17-25.
92. Jayaraman, T., Ondriasova, E., Ondrias, K., Harnick, D. J., and Marks, A. R. (1995) The Inositol 1,4,5-Trisphosphate Receptor is Essential for T-Cell Receptor Signaling. Proc Natl Acad Sci U S A. 92, 6007-6011.
93. Kovacs, B., and Tsokos, G. C. (1995) Cross-Linking of the Fas/APO-1 Antigen Suppresses the CD3-Mediated Signal Transduction Events in Human T Lymphocytes. J Immunol. 155, 5543-5549.
94. Russell, J. H., and Ley, T. J. (2002) Lymphocyte-Mediated Cytotoxicity. Annu Rev Immunol. 20, 323-370.
95. Lowin, B., Hahne, M., Mattmann, C., and Tschopp, J. (1994) Cytolytic T-Cell Cytotoxicity is Mediated through Perforin and Fas Lytic Pathways. Nature. 370, 650-652.
96. O'Brien, D., O'Connor, T., Shanahan, F., and O'Connell, J. (2002) Activation of the p38 MAPK and ERK1/2 Pathways is Required for Fas-Induced IL-8 Production in Colonic Epithelial Cells. Ann N Y Acad Sci. 973, 161-165.
97. Zhang, Y., Liu, Q., Zhang, M., Yu, Y., Liu, X., and Cao, X. (2009) Fas Signal Promotes Lung Cancer Growth by Recruiting Myeloid-Derived Suppressor Cells Via Cancer Cell-Derived PGE2. J Immunol. 182, 3801-3808.
98. Lee, S. M., Kim, E. J., Suk, K., and Lee, W. H. (2012) Stimulation of FasL Induces Production of Proinflammatory Mediators through Activation of Mitogen-Activated Protein Kinases and Nuclear Factor-kappaB in THP-1 Cells. Inflammation. 35, 1-10.
99. Rensing-Ehl, A., Hess, S., Ziegler-Heitbrock, H. W., Riethmuller, G., and Engelmann, H. (1995) Fas/Apo-1 Activates Nuclear Factor Kappa B and Induces Interleukin-6 Production. J Inflamm. 45, 161-174.
100. Becker, K. A., Henry, B., Ziobro, R., Tummler, B., Gulbins, E., and Grassme, H. (2012) Role of CD95 in Pulmonary Inflammation and Infection in Cystic Fibrosis. J Mol Med (Berl). 90, 1011-1023.
101. Ma, Y., Liu, H., Tu-Rapp, H., Thiesen, H. J., Ibrahim, S. M., Cole, S. M., and Pope, R. M. (2004) Fas Ligation on Macrophages Enhances IL-1R1-Toll-Like Receptor 4 Signaling and Promotes Chronic Inflammation. Nat Immunol. 5, 380-387.
102. Palao, G., Santiago, B., Galindo, M. A., Rullas, J. N., Alcami, J., Ramirez, J. C., and Pablos, J. L. (2006) Fas Activation of a Proinflammatory Program in Rheumatoid Synoviocytes and its Regulation by FLIP and Caspase 8 Signaling. Arthritis Rheum. 54, 1473-1481.
103. Guicciardi, M. E., and Gores, G. J. (2009) Life and Death by Death Receptors. FASEB J. 23, 1625-1637.
104. Farnand, A. W., Eastman, A. J., Herrero, R., Hanson, J. F., Mongovin, S., Altemeier, W. A., and Matute-Bello, G. (2011) Fas Activation in Alveolar Epithelial Cells Induces KC (CXCL1) Release by a MyD88-Dependent Mechanism. Am J Respir Cell Mol Biol. 45, 650-658.
105. Hohlbaum, A. M., Gregory, M. S., Ju, S. T., and Marshak-Rothstein, A. (2001) Fas Ligand Engagement of Resident Peritoneal Macrophages in Vivo Induces Apoptosis and the Production of Neutrophil Chemotactic Factors. J Immunol. 167, 6217-6224.
106. Niu, J., Azfer, A., Deucher, M. F., Goldschmidt-Clermont, P. J., and Kolattukudy, P. E. (2006) Targeted Cardiac Expression of Soluble Fas Prevents the Development of Heart Failure in Mice with Cardiac-Specific Expression of MCP-1. J Mol Cell Cardiol. 40, 810-820.
107. Batteux, F., Lores, P., Bucchini, D., and Chiocchia, G. (2000) Transgenic Expression of Fas Ligand on Thyroid Follicular Cells Prevents Autoimmune Thyroiditis. J Immunol. 164, 1681-1688.
108. Chervonsky, A. V., Wang, Y., Wong, F. S., Visintin, I., Flavell, R. A., Janeway, C. A.,Jr, and Matis, L. A. (1997) The Role of Fas in Autoimmune Diabetes. Cell. 89, 17-24.
109. Bohana-Kashtan, O., and Civin, C. I. (2004) Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance. Stem Cells. 22, 908-924.
110. Askenasy, N., Yolcu, E. S., Wang, Z., and Shirwan, H. (2003) Display of Fas Ligand Protein on Cardiac Vasculature as a Novel Means of Regulating Allograft Rejection. Circulation. 107, 1525-1531.
111. Kang, S. M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G., and Baekkeskov, S. (1997) Fas Ligand Expression in Islets of Langerhans does Not Confer Immune Privilege and Instead Targets them for Rapid Destruction. Nat Med. 3, 738-743.
112. Turvey, S. E., Gonzalez-Nicolini, V., Kingsley, C. I., Larregina, A. T., Morris, P. J., Castro, M. G., Lowenstein, P. R., and Wood, K. J. (2000) Fas Ligand-Transfected Myoblasts and Islet Cell Transplantation. Transplantation. 69, 1972-1976.
113. Takeuchi, T., Ueki, T., Nishimatsu, H., Kajiwara, T., Ishida, T., Jishage, K., Ueda, O., Suzuki, H., Li, B., Moriyama, N., and Kitamura, T. (1999) Accelerated Rejection of Fas Ligand-Expressing Heart Grafts. J Immunol. 162, 518-522.
114. Yamagami, S., Kawashima, H., Tsuru, T., Yamagami, H., Kayagaki, N., Yagita, H., Okumura, K., and Gregerson, D. S. (1997) Role of Fas-Fas Ligand Interactions in the Immunorejection of Allogeneic Mouse Corneal Transplants. Transplantation. 64, 1107-1111.
115. Hattori, K., Hirano, T., Miyajima, H., Yamakawa, N., Tateno, M., Oshimi, K., Kayagaki, N., Yagita, H., and Okumura, K. (1998) Differential Effects of Anti-Fas Ligand and Anti-Tumor Necrosis Factor Alpha Antibodies on Acute Graft-Versus-Host Disease Pathologies. Blood. 91, 4051-4055.
116. Mori, T., Nishimura, T., Ikeda, Y., Hotta, T., Yagita, H., and Ando, K. (1998) Involvement of Fas-Mediated Apoptosis in the Hematopoietic Progenitor Cells of Graft-Versus-Host Reaction-Associated Myelosuppression. Blood. 92, 101-107.
117. Lambert, C., Landau, A. M., and Desbarats, J. (2003) Fas-Beyond Death: A Regenerative Role for Fas in the Nervous System. Apoptosis. 8, 551-562.
118. Desbarats, J., Birge, R. B., Mimouni-Rongy, M., Weinstein, D. E., Palerme, J. S., and Newell, M. K. (2003) Fas Engagement Induces Neurite Growth through ERK Activation and p35 Upregulation. Nat Cell Biol. 5, 118-125.
119. Beier, C. P., Kolbl, M., Beier, D., Woertgen, C., Bogdahn, U., and Brawanski, A. (2007) CD95/Fas Mediates Cognitive Improvement After Traumatic Brain Injury. Cell Res. 17, 732-734.
120. Ugolini, G., Raoul, C., Ferri, A., Haenggeli, C., Yamamoto, Y., Salaun, D., Henderson, C. E., Kato, A. C., Pettmann, B., and Hueber, A. O. (2003) Fas/tumor Necrosis Factor Receptor Death Signaling is Required for Axotomy-Induced Death of Motoneurons in Vivo. J Neurosci. 23, 8526-8531.
121. Martin-Villalba, A., Herr, I., Jeremias, I., Hahne, M., Brandt, R., Vogel, J., Schenkel, J., Herdegen, T., and Debatin, K. M. (1999) CD95 Ligand (Fas-L/APO-1L) and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Mediate Ischemia-Induced Apoptosis in Neurons. J Neurosci. 19, 3809-3817.
122. Graham, E. M., Sheldon, R. A., Flock, D. L., Ferriero, D. M., Martin, L. J., O'Riordan, D. P., and Northington, F. J. (2004) Neonatal Mice Lacking Functional Fas Death Receptors are Resistant to Hypoxic-Ischemic Brain Injury. Neurobiol Dis. 17, 89-98.
123. Desbarats, J., and Newell, M. K. (2000) Fas Engagement Accelerates Liver Regeneration After Partial Hepatectomy. Nat Med. 6, 920-923.
124. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. (1993) Lethal Effect of the Anti-Fas Antibody in Mice. Nature. 364, 806-809.
125. Lee, P., Sata, M., Lefer, D. J., Factor, S. M., Walsh, K., and Kitsis, R. N. (2003) Fas Pathway is a Critical Mediator of Cardiac Myocyte Death and MI during Ischemia-Reperfusion in Vivo. Am J Physiol Heart Circ Physiol. 284, H456-63.
126. Jeremias, I., Kupatt, C., Martin-Villalba, A., Habazettl, H., Schenkel, J., Boekstegers, P., and Debatin, K. M. (2000) Involvement of CD95/Apo1/Fas in Cell Death After Myocardial Ischemia. Circulation. 102, 915-920.
127. Yang, J., Jones, S. P., Suhara, T., Greer, J. J., Ware, P. D., Nguyen, N. P., Perlman, H., Nelson, D. P., Lefer, D. J., and Walsh, K. (2003) Endothelial Cell Overexpression of Fas Ligand Attenuates Ischemia-Reperfusion Injury in the Heart. J Biol Chem. 278, 15185-15191.
128. de Oliveira, G. M., Diniz, R. L., Batista, W., Batista, M. M., Bani Correa, C., de Araujo-Jorge, T. C., and Henriques-Pons, A. (2007) Fas Ligand-Dependent Inflammatory Regulation in Acute Myocarditis Induced by Trypanosoma Cruzi Infection. Am J Pathol. 171, 79-86.
129. Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., and Nagata, S. (1994) Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand. Cell. 76, 969-976.
130. Schneider, P., Holler, N., Bodmer, J. L., Hahne, M., Frei, K., Fontana, A., and Tschopp, J. (1998) Conversion of Membrane-Bound Fas(CD95) Ligand to its Soluble Form is Associated with Downregulation of its Proapoptotic Activity and Loss of Liver Toxicity. J Exp Med. 187, 1205-1213.
131. Karray, S., Kress, C., Cuvellier, S., Hue-Beauvais, C., Damotte, D., Babinet, C., and Levi-Strauss, M. (2004) Complete Loss of Fas Ligand Gene Causes Massive Lymphoproliferation and Early Death, Indicating a Residual Activity of Gld Allele. J Immunol. 172, 2118-2125.
132. Wang, C. C., Zeng, Q., Hwang, L. A., Guo, K., Li, J., Liew, H. C., and Hong, W. (2006) Mouse Lymphomas Caused by an Intron-Splicing Donor Site Deletion of the FasL Gene. Biochem Biophys Res Commun. 349, 50-58.
133. Roths, J. B., Murphy, E. D., and Eicher, E. M. (1984) A New Mutation, Gld, that Produces Lymphoproliferation and Autoimmunity in C3H/HeJ Mice. J Exp Med. 159, 1-20.
134. Davidson, W. F., Giese, T., and Fredrickson, T. N. (1998) Spontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas-Fas Ligand Interactions. J Exp Med. 187, 1825-1838.
135. Cohen, P. L., and Eisenberg, R. A. (1991) Lpr and Gld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease. Annu Rev Immunol. 9, 243-269.
136. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., and Nagata, S. (1992) Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis. Nature. 356, 314-317.
137. Del-Rey, M., Ruiz-Contreras, J., Bosque, A., Calleja, S., Gomez-Rial, J., Roldan, E., Morales, P., Serrano, A., Anel, A., Paz-Artal, E., and Allende, L. M. (2006) A Homozygous Fas Ligand Gene Mutation in a Patient Causes a New Type of Autoimmune Lymphoproliferative Syndrome. Blood. 108, 1306-1312.
138. Canale, V. C., and Smith, C. H. (1967) Chronic Lymphadenopathy Simulating Malignant Lymphoma. J Pediatr. 70, 891-899.
139. Poppema, S., Maggio, E., and van den Berg, A. (2004) Development of Lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its Relationship to Fas Gene Mutations. Leuk Lymphoma. 45, 423-431.
140. Straus, S. E., Jaffe, E. S., Puck, J. M., Dale, J. K., Elkon, K. B., Rosen-Wolff, A., Peters, A. M., Sneller, M. C., Hallahan, C. W., Wang, J., Fischer, R. E., Jackson, C. M., Lin, A. Y., Baumler, C., Siegert, E., Marx, A., Vaishnaw, A. K., Grodzicky, T., Fleisher, T. A., and Lenardo, M. J. (2001) The Development of Lymphomas in Families with Autoimmune Lymphoproliferative Syndrome with Germline Fas Mutations and Defective Lymphocyte Apoptosis. Blood. 98, 194-200.
141. Wu, J., Wilson, J., He, J., Xiang, L., Schur, P. H., and Mountz, J. D. (1996) Fas Ligand Mutation in a Patient with Systemic Lupus Erythematosus and Lymphoproliferative Disease. J Clin Invest. 98, 1107-1113.
142. Suzuki, N., and Sakane, T. (1996) Abnormal Fas and Fas Ligand Expression of Lymphocytes in Patients with SLE. Nihon Rinsho. 54, 1955-1959.
143. Amasaki, Y., Kobayashi, S., Takeda, T., Ogura, N., Jodo, S., Nakabayashi, T., Tsutsumi, A., Fujisaku, A., and Koike, T. (1995) Up-Regulated Expression of Fas Antigen (CD95) by Peripheral Naive and Memory T Cell Subsets in Patients with Systemic Lupus Erythematosus (SLE): A Possible Mechanism for Lymphopenia. Clin Exp Immunol. 99, 245-250.
144. Liphaus, B. L., and Kiss, M. H. (2010) The Role of Apoptosis Proteins and Complement Components in the Etiopathogenesis of Systemic Lupus Erythematosus. Clinics (Sao Paulo). 65, 327-333.
145. Wang, G. Q., Bao, L., Zhao, X. X., Zhang, J., and Nan, K. J. (2013) Associations between Fas/FasL Polymorphisms and Susceptibility to Cervical Cancer: A Meta-Analysis. Tumour Biol. .
146. Zhang, B., Sun, T., Xue, L., Han, X., Zhang, B., Lu, N., Shi, Y., Tan, W., Zhou, Y., Zhao, D., Zhang, X., Guo, Y., and Lin, D. (2007) Functional Polymorphisms in FAS and FASL Contribute to Increased Apoptosis of Tumor Infiltration Lymphocytes and Risk of Breast Cancer. Carcinogenesis. 28, 1067-1073.
147. Sun, T., Zhou, Y., Li, H., Han, X., Shi, Y., Wang, L., Miao, X., Tan, W., Zhao, D., Zhang, X., Guo, Y., and Lin, D. (2005) FASL -844C Polymorphism is Associated with Increased Activation-Induced T Cell Death and Risk of Cervical Cancer. J Exp Med. 202, 967-974.
148. Liu, Y., Wen, Q. J., Yin, Y., Lu, X. T., Pu, S. H., Tian, H. P., Lou, Y. F., Tang, Y. N., Jiang, X., Lu, G. S., and Zhang, J. (2009) FASLG Polymorphism is Associated with Cancer Risk. Eur J Cancer. 45, 2574-2578.
149. Sun, T., Miao, X., Zhang, X., Tan, W., Xiong, P., and Lin, D. (2004) Polymorphisms of Death Pathway Genes FAS and FASL in Esophageal Squamous-Cell Carcinoma. J Natl Cancer Inst. 96, 1030-1036.
150. Zhang, X., Miao, X., Sun, T., Tan, W., Qu, S., Xiong, P., Zhou, Y., and Lin, D. (2005) Functional Polymorphisms in Cell Death Pathway Genes FAS and FASL Contribute to Risk of Lung Cancer. J Med Genet. 42, 479-484.
151. Linkermann, A., Qian, J., Lettau, M., Kabelitz, D., and Janssen, O. (2005) Considering Fas Ligand as a Target for Therapy. Expert Opin Ther Targets. 9, 119-134.
152. Murata, J., Abe, R., and Shimizu, H. (2008) Increased Soluble Fas Ligand Levels in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Preceding Skin Detachment. J Allergy Clin Immunol. 122, 992-1000.
153. Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J. H., Tschopp, J., and French, L. E. (1998) Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin. Science. 282, 490-493.
154. Paul, C., Wolkenstein, P., Adle, H., Wechsler, J., Garchon, H. J., Revuz, J., and Roujeau, J. C. (1996) Apoptosis as a Mechanism of Keratinocyte Death in Toxic Epidermal Necrolysis. Br J Dermatol. 134, 710-714.
155. Singer, G. G., and Abbas, A. K. (1994) The Fas Antigen is Involved in Peripheral but Not Thymic Deletion of T Lymphocytes in T Cell Receptor Transgenic Mice. Immunity. 1, 365-371.
156. Rubio, C. F., Kench, J., Russell, D. M., Yawger, R., and Nemazee, D. (1996) Analysis of Central B Cell Tolerance in Autoimmune-Prone MRL/lpr Mice Bearing Autoantibody Transgenes. J Immunol. 157, 65-71.
157. Schram, B. R., and Rothstein, T. L. (2003) NF-Kappa B is Required for Surface Ig-Induced Fas Resistance in B Cells. J Immunol. 170, 3118-3124.
158. Hennino, A., Berard, M., Krammer, P. H., and Defrance, T. (2001) FLICE-Inhibitory Protein is a Key Regulator of Germinal Center B Cell Apoptosis. J Exp Med. 193, 447-458.
159. Rathmell, J. C., Townsend, S. E., Xu, J. C., Flavell, R. A., and Goodnow, C. C. (1996) Expansion Or Elimination of B Cells in Vivo: Dual Roles for CD40- and Fas (CD95)-Ligands Modulated by the B Cell Antigen Receptor. Cell. 87, 319-329.
160. Wenzel, J., Sanzenbacher, R., Ghadimi, M., Lewitzky, M., Zhou, Q., Kaplan, D. R., Kabelitz, D., Feller, S. M., and Janssen, O. (2001) Multiple Interactions of the Cytosolic Polyproline Region of the CD95 Ligand: Hints for the Reverse Signal Transduction Capacity of a Death Factor. FEBS Lett. 509, 255-262.
|Science Writers||Anne Murray|
|Authors||Kuan-Wen Wang, Ming Zeng, Bruce Beutler|